Vivimed Labs Limited (NSE: VIVIMEDLAB | BSE: 532660)

By Raveendran R | Updated on:

Source: Vivimed Labs Limited Annual Report FY 2024-25 (Fiscal Year Ended March 31, 2025)

Metrics for FY 2024-25 Ended Mar 31, 2025
Profit & Loss (₹ Cr)
Revenue
₹116.27 Cr (▼ 22.0%)
Prev Year: ₹149.07 Cr
Gross Profit
₹56.42 Cr (▼ 27.3%)
Prev Year: ₹77.59 Cr
Operating Profit
-₹28.90 Cr (▲ 33.4%)
Prev Year: -₹43.39 Cr
Net Profit
-₹31.96 Cr (▲ 29.7%)
Prev Year: -₹45.45 Cr
Ratios & Margins (% / x)
Gross Margin
48.52 % (▼ 352 bps)
Prev Year: 52.05 %
Operating Margin
-24.86 % (▲ 425 bps)
Prev Year: -29.11 %
PAT Margin
-27.49 % (▲ 300 bps)
Prev Year: -30.49 %
ROCE
-5.64 % (▲ 239 bps)
Prev Year: -8.03 %
ROCE (3Y Avg)
-5.20 %
FY22–FY25 (3Y Avg)
ROA
-3.47 % (▲ 131 bps)
Prev Year: -4.78 %
Asset Turnover
0.13x (▼ 0.03 pts)
Prev Year: 0.16x
Balance Sheet (₹ Cr)
Total Assets
₹920.83 Cr (▼ 3.2%)
Prev Year: ₹950.91 Cr
Current Assets
₹327.55 Cr (▼ 4.4%)
Prev Year: ₹342.58 Cr
Total Liabilities
₹956.00 Cr (- 0.0%)
Prev Year: ₹956.37 Cr
Current Liabilities
₹408.20 Cr (▼ 0.5%)
Prev Year: ₹410.33 Cr
Total Debt
₹376.33 Cr (▼ 0.2%)
Prev Year: ₹376.93 Cr
Total Equity
-₹35.17 Cr (▼ 544.1%)
Prev Year: -₹5.46 Cr
Working Capital
-₹80.65 Cr (▼ 19.0%)
Prev Year: -₹67.75 Cr
Ratios & Margins (% / x)
Current Ratio
0.80x (▼ 0.03 pts)
Prev Year: 0.83x
Debt to Assets
0.41x (▲ 0.01 pts)
Prev Year: 0.40x
Cash Flow (₹ Cr)
Operating Cash Flow
-₹1.75 Cr (▲ 92.7%)
Prev Year: -₹23.99 Cr
CapEx
₹4.53 Cr (▲ 122.1%)
Prev Year: ₹2.04 Cr
Free Cash Flow
-₹6.28 Cr (▲ 75.9%)
Prev Year: -₹26.03 Cr
Ratios & Margins (% / x)
FCF Margin
-5.40 % (▲ 1206 bps)
Prev Year: -17.46 %
Cash ROCE
-0.34 % (▲ 410 bps)
Prev Year: -4.44 %
Cash ROCE (4Y Avg)
29.89 %
FY22–FY25 (4Y Avg)
CF to Debt
-0.00x (▲ 0.06 pts)
Prev Year: -0.06x

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Vivimed Labs Limited
Corporate Identity Number (CIN) L02411KA1988PLC009465
ISIN INE526G01021
Stock Exchange Listings BSE Limited (Scrip Code: 532660) | National Stock Exchange of India Limited (Symbol: VIVIMEDLAB)
Year of Inception 1988
Key Founders / Promoters Mr. Santosh Varalwar & Dr. Manohar Rao Varalwar
Registered Office Plot No. 78/A, Kolhar Industrial Area, Bidar – 585403, Karnataka, India
Corporate Headquarters D. No. 6-3-866/1/G1, 3rd Floor, GMR Towers, Greenlands, Begumpet, Hyderabad, Telangana – 500016, India
Contact Coordinates Tel: +91 (0) 40-6608-6608 | Fax: +91 (0) 40-6608-6699 | Email: info@vivimedlabs.com / yugandhar.kopparthi@vivimedlabs.com
Managing Director Mr. Santosh Varalwar
Chairman cum Whole Time Director Dr. Manohar Rao Varalwar
Chief Financial Officer (CFO) Mr. Phanindernath Petasonti (Appointed w.e.f. January 10, 2025)
Company Secretary & Compliance Officer Mr. Yugandhar Kopparthi
Promoter Holding Group Varalwar Family & BBR Projects Private Limited
Core Sector & Industry Pharmaceuticals & Finished Dosage Formulations (FDF) / Contract Development & Manufacturing Organisation (CDMO)
Permanent Workforce Strength 586 Employees (as on March 31, 2025)
Operating Footprint 6 Manufacturing Facilities (Across Karnataka, Telangana, Uttarakhand & Maharashtra) and 1 Dedicated R&D Centre
Statutory Auditors M/s SVRL & Co., Chartered Accountants, Hyderabad
Secretarial Auditor Mr. N. V. S. S. Suryanarayana Rao, Practicing Company Secretary, Hyderabad
Cost Auditors M/s J K & Co, Cost Accountants, Hyderabad
Registrar & Share Transfer Agent (RTA) Aarthi Consultants Private Limited, 1-2-285, Domalguda, Hyderabad – 500029, Telangana

🏢 The Corporate Identity: Vivimed Labs Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Vivimed Labs Limited is an India-headquartered pharmaceutical and specialty enterprise that has transitioned from its origins as a domestic formulation contract manufacturer into an export-focused supplier of Finished Dosage Forms (FDF) and active contract development and manufacturing partner. The company operates five certified manufacturing facilities alongside a specialized research and development hub located in Hyderabad, delivering prescription generics, Over-The-Counter (OTC) monographs, and ophthalmic formulations across regulated and semi-regulated international markets.

The company’s overarching strategic vision is to establish itself as a fully integrated Branded Formulations and CDMO partner of choice across global and domestic markets. Historically structured across dual verticals comprising Active Pharmaceutical Ingredients (API) CDMO operations and Specialty Chemicals, Vivimed Labs has undertaken an extensive structural reorganization. The company divested legacy chemical product lines and debt-heavy overseas assets to concentrate its resources on finished dosage formulations, leveraging its regulatory accreditations from Health Canada and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) to access high-entry-barrier jurisdictions across North America, the Commonwealth of Independent States (CIS), Latin America, and the Middle East.

The Founders, Promoters & Their Legacy

The entrepreneurial foundation of Vivimed Labs was established by the Varalwar family, combining technical veterinary science expertise with international merchant shipping acumen. The promoter leadership has navigated the group through multiple growth phases, marked by domestic contract manufacturing, overseas cross-border acquisitions, and subsequent debt-rationalisation divestments:

  • Mr. Santosh Varalwar (Managing Director): Holding a management degree, Mr. Santosh Varalwar worked with the Shipping Corporation of India (SCI) for seven years, gaining merchant trade experience and international exposure before entering entrepreneurship in 1985 through VVS Pharmaceuticals. He spearheaded the acquisition of EMGI Pharmaceuticals and Chemicals Private Limited in Bidar, orchestrating its listing on the BSE and NSE in 2005. He led the company’s global expansion, executing international acquisitions across the United Kingdom, the United States, Spain, and Hungary, and now leads the strategic restructuring of the company’s operational pipeline.
  • Dr. Manohar Rao Varalwar (Chairman cum Whole Time Director): Aged 89 years, Dr. Varalwar retired as Joint Director of The Veterinary Biological and Research Institute (VBRI), having earned his post-graduation in Veterinary Sciences from Edinburgh University, United Kingdom. With more than 55 years of combined administrative, biotechnological, and pharmaceutical manufacturing experience, he established the original quality-control infrastructure at VVS Pharmaceuticals and pioneered the group’s early biological processing and formulation technologies.
  • Mr. Sandeep Varalwar (Whole Time Director): A pharmacy graduate with over 32 years of operational experience in the pharmaceutical manufacturing and marketing sectors, Mr. Sandeep Varalwar has directed the technical execution of the formulations business, overseeing manufacturing discipline, plant compliance, and production scaling across the group’s facilities.

The Journey: Corporate History & Key Milestones

Over nearly four decades, Vivimed Labs has evolved through distinct operating phases:

  • 1988–2004: Inception and API Expansion: Commenced operations as a contract manufacturer for pharmaceutical formulations before expanding into API and bulk drug manufacturing at Bidar, Karnataka, producing molecules such as ibuprofen, chlorzoxazone, and nalidixic acid. The company made an early entry into specialty chemicals with the grant of the Indian patent for VIV-20 (Triclosan).
  • 2005–2010: Public Listing and Global Footprint: Achieved approval from Unilever for supplying VIV-20 and Vivcal-G across Asian manufacturing hubs. Successfully completed its Initial Public Offering (IPO) in 2005, listing on both the BSE and NSE. Expanded manufacturing by introducing Small Volume Parenterals (SVP) and broad specialty chemical assets, serving international personal care corporations including L’Oréal and Procter & Gamble. Entered inorganic global expansion by acquiring UK-based James Robinson to scale active ingredients.
  • 2011–2019: Scale, Cross-Border M&A, and High-Potency API: Acquired Barcelona-based Uquifa for USD 55 million in 2011, securing three USFDA-approved manufacturing locations. Followed this with domestic acquisitions of Klar Sehen and Octantis Nobel to enter branded ophthalmic and generic markets. Acquired Alathur manufacturing assets and Finoso Pharma Private Limited (2013) to bolster formulation R&D. In 2018, acquired Budapest-based CDMO player Soneas through Uquifa to pivot toward high-end chemical synthesis.
  • 2020–2024: Debt Rationalisation and Portfolio De-leveraging: Divested the Personal Care Ingredients business to Clariant, monetized majority ownership in subsidiary Uquifa (retaining a minority interest), and divested legacy hair dye and photochromic portfolios to repay corporate borrowings. Concentrated operating capital on Finished Dosage Formulations with dedicated export mandates.
  • FY 2024-25: Consolidation and Emerging Market Regulatory Inroads: Advanced regulatory dossiers across Canada, Ukraine, CIS markets, Latin America, and the GCC. Secured out-licensing deals in Saudi Arabia and commercialized Bilastine, Rivaroxaban, and Chlorthalidone across key overseas territories while initiating broad balance sheet restructuring.

The Corporate Umbrella & Group Structure

Vivimed Labs Limited acts as the parent operating entity for a corporate structure comprising Indian and international operating and investment vehicles. Research, development, and analytical capabilities are consolidated through Finoso Pharma Private Limited in Hyderabad, while international distribution, intellectual property holding, and historical multi-jurisdictional investments reside within offshore holding companies incorporated across Hong Kong, Mauritius, and the United States.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

In accordance with Ind AS 108 Operating Segments, Vivimed Labs reports its operational results under two core business divisions: Pharmaceuticals and Speciality Chemicals. During the financial year ended March 31, 2025, the company’s business was driven almost entirely by its pharmaceutical operations following the strategic divestment and operational wind-down of legacy chemical product lines.

Segment Name FY 2024-25 Revenue (₹ Crores) % Share of Total Revenue FY 2023-24 Revenue (₹ Crores) % Share of Total Revenue FY 2024-25 Segment Results / PBIT (₹ Crores) FY 2024-25 Segment Assets (₹ Crores) FY 2024-25 Segment Liabilities (₹ Crores) Latest YoY (%)
Pharma 116.27 100.00% 143.17 96.04% (31.85) 777.91 819.60 -18.79%
Speciality Chemicals 0.00 0.00% 5.90 3.96% 0.00 142.92 136.40 -100.00%
Total Segment Performance 116.27 100.00% 149.07 100.00% (31.85) 920.83 956.00 -22.00%

Consolidated revenue from operations contracted by 22.00% from ₹149.07 Crores in FY 2023-24 to ₹116.27 Crores in FY 2024-25. The operating segment result (loss before interest and unallocable items) narrowed from a loss of ₹53.37 Crores in FY 2023-24 (comprising a ₹27.33 Crore loss in Pharma and a ₹26.03 Crore loss in Speciality Chemicals) to a loss of ₹31.85 Crores in FY 2024-25, reflecting the operational closure of the non-performing specialty chemicals lines.

The Product & Service Catalog (with Operational KPIs & Order Book)

Vivimed Labs offers a portfolio focused on solid oral dosage forms, liquid orals, ophthalmic drops, and specialized contract research services:

  • Finished Dosage Formulations (FDF): Manufacture of tablets, hard gelatin capsules, oral suspensions, dry syrups, ointments, and eye drops spanning cardiovascular, central nervous system, anti-histaminic, anti-diabetic, and analgesic therapeutic segments.
  • Contract Development & Manufacturing Services (CDMO): Technical transfer, pilot-scale synthesis, formulation optimization, analytical method development, and regulatory dossier preparation for global pharmaceutical marketing authorization holders.
  • Finoso Pharma Research Activities: In FY 2024-25, Finoso Pharma successfully executed 16 new research projects, completing critical pivotal bioequivalence (BE) studies for target commercial molecules and providing regulatory response packages for client submissions across the European Union, Australia, and the Middle East.
  • Commercial Production Releases: Achieved commercial batch scale-up and deliveries for Bilastine Tablets (non-sedating second-generation anti-histamine), Rivaroxaban Tablets (direct factor Xa oral anticoagulant), and Edoxaban Tablets.
  • Export Orders & Filings: Executed an initial commercial shipment of Bilastine in Kyrgyzstan valued at USD 15,000, fulfilled a strategic oral liquids purchase order in Uzbekistan valued at USD 200,000 during Q4 FY 2024-25, and submitted regulatory filings for Empagliflozin across Mexico, Saudi Arabia, and Zambia.

The Names You Know: Key Brands & Flagship Portfolio

The company markets and out-licenses generic and branded formulations across diverse domestic and international therapeutic markets:

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Bilastine Tablets Anti-histamine / Anti-allergy Export Generics (Ukraine, Kyrgyzstan, CIS, ROW); fast-acting allergic rhinitis treatment
Rivaroxaban Tablets Cardiovascular / Anticoagulant Domestic & Export Formulations; stroke prevention in atrial fibrillation and deep vein thrombosis
Edoxaban Tablets Cardiovascular / Anticoagulant Export Dossier Filings (Bolivia, Chile); novel oral anticoagulant therapies
Chlorthalidone (10mg & 20mg) Cardiovascular / Thiazide Diuretic Regulated Market (Canada); commercialized long-acting diuretic for hypertension management
Allopurinol (100mg, 200mg, 300mg) Anti-gout / Xanthine Oxidase Inhibitor Regulated Market (Canada); approved prescription product for chronic gout and hyperuricemia
Empagliflozin (10mg & 25mg) Endocrinology / SGLT2 Inhibitor Canada (Commercial Launch slated for May 2026), Saudi Arabia, Mexico, Zambia; Type-2 diabetes therapy
Orzobac Vaginal Tablets Gynecological Anti-infective Export Brand (Azerbaijan); specialized anti-microbial formulation
Fluban / Fluban Forte Sachets Respiratory & Cold Formulation CIS Markets (Ukraine, Kyrgyzstan); combination relief sachets
Para + CPM Tablets & Liquids Analgesic / Anti-pyretic / Anti-histaminic CIS Markets (Kyrgyzstan, Uzbekistan); pediatric and adult cold combinations

Mapping the Domestic & Global Reach (India vs. Exports)

Vivimed Labs serves both the Indian domestic market through institutional supply and contract manufacturing, and international markets via direct export registrations and CDMO partnerships. During FY 2024-25, export revenues expanded significantly, demonstrating an operational pivot away from sluggish domestic branded sales.

Geographic Destination FY 2024-25 Revenue (₹ Crores) % Share of Total Revenue FY 2023-24 Revenue (₹ Crores) % Share of Total Revenue Latest YoY (%)
Domestic Sales (India) 90.82 78.11% 140.64 94.34% -35.42%
Export Sales (International) 25.45 21.89% 8.43 5.66% +201.90%
Total Operating Revenue 116.27 100.00% 149.07 100.00% -22.00%

Export revenues increased more than threefold in FY 2024-25, reaching ₹25.45 Crores compared to ₹8.43 Crores in the preceding fiscal year, driven by product registrations and shipments across Canada, Ukraine, Uzbekistan, Kyrgyzstan, Azerbaijan, and dossier licensing agreements in Saudi Arabia. Conversely, domestic sales contracted from ₹140.64 Crores to ₹90.82 Crores, impacted by field force attrition and restructuring of the medical representative network in the domestic branded division.

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The manufacturing infrastructure of Vivimed Labs comprises certified plants located across India’s key industrial hubs, supported by central formulation development laboratories:

  • Specialty Chemicals Facility (Bidar, Karnataka): Plot No. 78/A, Kolhar Industrial Area, Bidar – 585403, Karnataka. Serves as the historical site for chemical synthesis and API bulk drug intermediates.
  • Formulations Facility I (Jeedimetla, Telangana): D-125 & 128, Phase III, Jeedimetla Industrial Estate, Hyderabad – 500055, Telangana. Upgraded to PIC/S GMP standards; produces solid oral dosage forms.
  • Formulations Facility II (Jeedimetla, Telangana): Plot No. 8, Phase V, IDA Jeedimetla, Hyderabad – 500055, Telangana. Focused on oral formulations and technical pilot batches.
  • Kashipur Plant I (Kundeshwari, Uttarakhand): Plot No. 25, Kundeshwari Village, Kashipur, Udham Singh Nagar – 244713, Uttarakhand. Large-scale formulations manufacturing unit.
  • Kashipur Plant II (Kishlay, Uttarakhand): Kishlay, Kashipur – 110001, Uttarakhand. Liquid orals and generic manufacturing.
  • Haridwar Formulations Plant (Haridwar, Uttarakhand): D-9, Industrial Area, Haridwar – 249401, Uttarakhand. Dedicated to oral dosage forms, tablets, and dry syrups.
  • Mumbai Operational Facility (Goregaon, Maharashtra): 130, Shanta Industrial Estate, 1st Floor, I.B. Patel Road, Goregaon (East), Mumbai – 400063, Maharashtra.
  • Central R&D Centre (Nacharam, Hyderabad): H. No. A-1/ABC, Main Road, Nacharam IDA, Hyderabad – 500076, Telangana. Features advanced formulation, pre-formulation, analytical chemistry, and stability chambers; holds regulatory inspection accreditations including Health Canada for formulation R&D.

📊 The Financial Health: The Numbers Simplified

Multi-Year Financial Highlights

The operational trajectory of Vivimed Labs over recent fiscal years reflects severe balance sheet pressure, debt restructuring attempts, and business contraction, alongside narrowing operational losses:

Financial Metric FY 2024-25 (₹ Crores) FY 2023-24 (₹ Crores) FY 2022-23 (₹ Crores) FY 2021-22 (₹ Crores) Latest YoY (%)
Revenue from Operations 116.27 149.07 184.20 239.00 -22.00%
EBITDA (8.68) (23.45) (186.00) (7.00) -62.99%
Profit / (Loss) After Tax (PAT) (31.96) (45.45) (329.00) (68.00) -29.68%
Total Equity / Net Worth (35.17) (5.46) 35.00 364.00 +544.14%
Operating Cash Flow (CFO) (1.75) (23.99) 44.00 (5.00) -92.71%

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

Consolidated revenue from operations for the financial year ended March 31, 2025 stood at ₹116.27 Crores, down from ₹149.07 Crores in FY 2023-24. Consolidated net loss for the year totaled ₹31.96 Crores, an improvement compared to the net loss of ₹45.45 Crores recorded in the prior year, driven by operational rationalization across overheads and raw material expenses.

Statement of Profit and Loss (Consolidated) FY 2024-25 (₹ Crores) FY 2023-24 (₹ Crores) Latest YoY (%)
Revenue from Operations 116.27 149.07 -22.00%
Other Income 4.37 9.98 -56.21%
Total Income 120.64 159.05 -24.15%
Cost of Materials Consumed 57.76 89.55 -35.50%
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade 2.09 (18.07) N/M
Employee Benefit Expenses 28.39 34.16 -16.89%
Finance Costs 2.95 2.43 +21.40%
Depreciation and Amortisation Expense 20.22 19.94 +1.40%
Other Expenses 41.07 76.87 -46.57%
Total Expenses 152.49 204.87 -25.57%
Profit / (Loss) Before Tax (31.85) (45.82) -30.49%
Tax Expense:
Current Tax 0.00 0.23 -100.00%
Prior Period Taxes 0.00 0.02 -100.00%
Deferred Tax (0.11) (0.40) -72.50%
Total Tax Expense 0.11 (0.38) N/M
Profit / (Loss) for the Period (31.96) (45.45) -29.68%
Other Comprehensive Income / (Loss):
Re-measurement Gains / (Losses) on Defined Benefit Plans 0.42 0.59 -28.81%
Income Tax Effect 0.04 (0.03) N/M
Total Other Comprehensive Income / (Loss), Net of Tax 0.46 0.56 -17.86%
Total Comprehensive Income for the Year (31.50) (44.88) -29.81%
Basic Earnings Per Equity Share (Par Value ₹2 each) (₹) (3.85) (5.48) -29.74%
Diluted Earnings Per Equity Share (Par Value ₹2 each) (₹) (3.74) (5.32) -29.70%

Operating profitability metrics reflect ongoing structural deficits:

  • Operating Profit (EBIT): Evaluated as Loss Before Tax (-₹31.85 Crores) plus Finance Costs (₹2.95 Crores) minus Other Income (₹4.37 Crores), yielding an EBIT of -₹33.27 Crores in FY 2024-25, compared to -₹48.27 Crores in FY 2023-24.
  • Operating Margin (%): Computed at -28.61% for FY 2024-25 versus -32.38% in FY 2023-24.
  • Critical Statutory Audit Qualification Regarding Unaccrued Interest: As highlighted in the Independent Auditor’s Report, the company did not accrue finance interest expense estimated at approximately ₹57.44 Crores for FY 2024-25 on its non-performing bank credit facilities. Had this interest been recognized on an accrual basis in compliance with Ind AS, reported losses would have been higher by ₹57.44 Crores, resulting in an adjusted pre-tax loss of ₹89.29 Crores.

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The consolidated balance sheet of Vivimed Labs highlights severe balance-sheet erosion, with negative total equity of -₹35.17 Crores as of March 31, 2025, driven by accumulated retained earnings deficits of -₹322.27 Crores.

Consolidated Balance Sheet as at March 31 FY 2024-25 (₹ Crores) FY 2023-24 (₹ Crores) Latest YoY (%)
A. ASSETS
1. Non-Current Assets
Property, Plant and Equipment 254.40 262.86 -3.22%
Capital Work-in-Progress (CWIP) 17.11 20.65 -17.14%
Goodwill 16.91 16.91 0.00%
Other Intangible Assets 136.36 138.15 -1.30%
Financial Assets: Investments 168.50 168.50 0.00%
Deferred Tax Assets (Net) 0.00 0.44 -100.00%
Other Non-Current Assets 0.00 0.82 -100.00%
Total Non-Current Assets 593.28 608.33 -2.47%
2. Current Assets
Inventories 58.76 64.06 -8.27%
Financial Assets: Trade Receivables 74.11 82.82 -10.52%
Financial Assets: Cash and Cash Equivalents 0.71 1.63 -56.44%
Financial Assets: Bank Balances Other Than Above 0.00 0.40 -100.00%
Financial Assets: Loans 46.93 41.42 +13.30%
Financial Assets: Other Financial Assets 48.53 70.15 -30.82%
Current Tax Assets 10.19 10.01 +1.80%
Other Current Assets 88.33 72.09 +22.53%
Total Current Assets 327.55 342.58 -4.39%
TOTAL ASSETS 920.83 950.91 -3.16%
B. EQUITY AND LIABILITIES
1. Equity
Equity Share Capital 16.58 16.58 0.00%
Other Equity (51.75) (22.04) +134.80%
Total Equity (Net Worth) (35.17) (5.46) +544.14%
2. Non-Current Liabilities
Financial Liabilities: Borrowings 63.62 63.57 +0.08%
Other Financial Liabilities 470.23 467.92 +0.49%
Provisions 4.82 4.90 -1.63%
Deferred Tax Liabilities (Net) 8.62 9.03 -4.54%
Other Non-Current Liabilities 0.52 0.63 -17.46%
Total Non-Current Liabilities 547.81 546.05 +0.32%
3. Current Liabilities
Financial Liabilities: Borrowings 312.71 313.36 -0.21%
Trade Payables 39.43 44.07 -10.53%
Other Financial Liabilities 11.85 17.39 -31.86%
Other Current Liabilities 24.67 16.05 +53.71%
Provisions 1.48 1.39 +6.47%
Current Tax Liabilities 18.06 18.06 0.00%
Total Current Liabilities 408.20 410.33 -0.52%
Total Liabilities 956.00 956.37 -0.04%
TOTAL EQUITY AND LIABILITIES 920.83 950.91 -3.16%

Key balance sheet observations, debt structures, and working capital cycles reveal significant leverage stress:

  • Total Debt Structure: Non-Current Borrowings stood at ₹63.62 Crores (comprising Foreign Currency Convertible Bonds [FCCB] from IFC of ₹62.95 Crores, sales tax deferment loans of ₹0.37 Crores, and vehicle loans of ₹0.30 Crores), while Current Borrowings totaled ₹312.71 Crores (working capital cash credit facilities from SBI, Indian Bank, and Bank of Bahrain & Kuwait). Combined recorded debt stands at ₹376.33 Crores.
  • NPA Defaults & DRT Proceedings: Borrowings aggregating to ₹374.46 Crores are in default and classified as Non-Performing Assets (NPAs) by lending banks and financial institutions. Lead lender State Bank of India (carrying an outstanding exposure of ₹181.00 Crores at 16.50% interest) has filed a debt recovery petition before the Debts Recovery Tribunal (DRT). The company is actively pursuing a One-Time Settlement (OTS) and loan restructuring.
  • Trade Receivables & Working Capital Days: Outstanding trade receivables stood at ₹74.11 Crores as of March 31, 2025, against ₹82.82 Crores in FY 2023-24. Receivable days stood elevated at approximately 233 days of sales, while inventory days stood at approximately 184 days, resulting in a prolonged cash conversion cycle.
  • Capital Employed: Total Assets (₹920.83 Crores) minus Total Current Liabilities (₹408.20 Crores) yields ₹512.63 Crores in total capital employed.

Cash Flow: Tracking the Money Movement

The consolidated statement of cash flows indicates continued liquidity constraints, with operational cash generation remaining negative as the company allocated operational collections toward working capital stabilization and maintenance capital spending:

Consolidated Statement of Cash Flows FY 2024-25 (₹ Crores) FY 2023-24 (₹ Crores) Latest YoY (%)
Profit / (Loss) Before Tax (31.50) (45.82) -31.25%
Adjustments: Depreciation and Amortisation 20.22 19.94 +1.40%
Adjustments: Finance Costs 2.95 2.43 +21.40%
Operating Profit Before Working Capital Changes (8.33) (23.45) -64.48%
Working Capital: (Increase) / Decrease in Trade Receivables 8.71 (8.66) N/M
Working Capital: (Increase) / Decrease in Inventories 5.31 15.70 -66.18%
Working Capital: (Increase) / Decrease in Loans & Other Financial Assets (13.42) (1.62) +728.40%
Working Capital: (Increase) / Decrease in Other Operating Assets 6.02 (10.65) N/M
Working Capital: Increase / (Decrease) in Trade Payables (4.64) (11.16) -58.42%
Working Capital: Increase / (Decrease) in Other Liabilities & Provisions 4.69 1.08 +334.26%
Cash Generated from / (Used in) Operations (1.66) (24.09) -93.11%
Income Taxes Paid (Net) (0.09) 0.09 N/M
Net Cash from / (Used in) Operating Activities (1.75) (23.99) -92.71%
Cash Flows from Investing Activities:
Purchase of Property, Plant and Equipment (CapEx including CWIP), Net 4.53 2.04 +122.06%
Investments Realised / (Made) During the Year 0.00 30.33 -100.00%
Net Cash from / (Used in) Investing Activities (4.53) 28.29 N/M
Cash Flows from Financing Activities:
Proceeds from / (Repayment of) Long-Term Borrowings (Net) -5.64% 8.03% –
Proceeds from / (Repayment of) Short-Term Borrowings (Net) -5.64% 8.03% –
Interest Paid (2.95) (2.43) +21.40%
Other Financing Inflows / Non-Cash Movement 7.99 (8.00) N/M
Net Cash from / (Used in) Financing Activities 4.96 (6.03) N/M
Net Increase / (Decrease) in Cash & Cash Equivalents (1.32) (1.74) -24.14%
Cash and Cash Equivalents at the Beginning of the Year 2.03 3.76 -46.01%
Cash and Cash Equivalents at the End of the Year 0.71 2.03 -65.02%

Funding the Future: CapEx, CWIP, R&D & Foreign Exchange

Vivimed Labs maintained restrained capital expenditure while supporting necessary regulatory filing commitments:

  • CapEx Additions & CWIP: Direct gross fixed asset additions during FY 2024-25 were ₹8.25 Crores, primarily directed toward plant machinery and laboratory compliance equipment, offset by ₹3.54 Crores in CWIP capitalisation. Capital Work-in-Progress closed at ₹1.71 Crores, with all projects aged between 1 to 3 years.
  • Research & Development Expenditure: Operating R&D expenditure incurred was ₹0.42 Crores in FY 2024-25, compared to ₹0.21 Crores in FY 2023-24, representing approximately 0.36% of operating revenues. R&D focuses on pre-formulation, bioequivalence testing, and dossier filings for emerging and regulated markets.
  • Section 134(3)(m) Foreign Exchange Earnings & Outgo: On a standalone statutory basis, foreign exchange earnings realized in FY 2024-25 were ₹0.38 Crores (down from ₹14.30 Crores in FY 2023-24). Standalone foreign exchange outgo was ₹0.00 Crores in FY 2024-25 (compared to ₹0.68 Crores in FY 2023-24).
  • Energy Conservation Tracking: Total electricity purchased across manufacturing units was 2.39 million kWh, amounting to ₹2.46 Crores (average tariff of ₹10.27/kWh), compared to 2.79 million kWh and ₹2.63 Crores in FY 2023-24. Captive diesel generation consumed 0.10 million litres, incurring ₹0.96 Crores.

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

The governance structure is overseen by a reconstituted 6-member Board of Directors, balanced equally between executive promoter leadership and independent directors:

Name of Director / KMP Designation / Role DIN Category
Santosh Varalwar Managing Director 00054763 Executive / Promoter Director
Dr. Manohar Rao Varalwar Chairman cum Whole Time Director 00059815 Executive / Promoter Director
Sandeep Varalwar Whole Time Director 01682951 Executive / Promoter Director
Aparna Bidarkar Independent Director 05112945 Non-Executive / Independent Director
Subbarathnamma Palepu Independent Director (Lead Independent Director) 09432984 Non-Executive / Independent Director
Jarugula Siva Prasad Independent Director (Audit Committee Chairman) 07087695 Non-Executive / Independent Director
Phanindernath Petasonti Chief Financial Officer (CFO) – Key Managerial Personnel
Yugandhar Kopparthi Company Secretary & Compliance Officer – Key Managerial Personnel

During FY 2024-25, several changes occurred in the board’s composition:

  • Independent Director Dr. Hari Gopal Jamalapuram passed away on November 19, 2024.
  • Non-Executive Director Mr. Subhash Varalwar resigned from the Board on December 11, 2024 due to ill health.
  • Ms. Subbarathnamma Palepu and Mr. Jarugula Siva Prasad were inducted as Independent Directors on December 11, 2024 for five-year terms.
  • Mr. Phanindernath Petasonti was appointed Chief Financial Officer on January 10, 2025, succeeding Mr. Ramakanta Tripathy.

Who Owns the Stock? Shareholding Pattern

The total paid-up equity share capital of Vivimed Labs Limited as of March 31, 2025 is ₹16.58 Crores, divided into 8,29,13,915 equity shares of face value ₹2/- each. Trading in the company’s equity shares has been suspended on the stock exchanges due to penal reasons arising from regulatory and compliance defaults.

Category of Shareholder No. of Shareholders Total Number of Shares % Shareholding
Promoter & Promoter Group (Indian) 16 1,73,64,635 20.94%
Individuals / Hindu Undivided Families 15 78,69,131 9.49%
Corporate Bodies (BBR Projects Pvt Ltd) 1 94,95,504 11.45%
Foreign Portfolio Investors (FPIs) 5 13,59,791 1.64%
Central / State Governments 1 96,130 0.12%
Resident Individuals (Capital up to ₹0.0200 Crores) 48,255 4,24,09,023 51.15%
Resident Individuals (Capital above ₹0.0200 Crores) 24 56,09,386 6.77%
Foreign Corporate Bodies (Kitara PIIN 1102) 1 77,66,387 9.37%
Non-Resident Indians (NRIs – Non-Repatriable) 447 37,57,975 4.53%
Domestic Corporate Bodies 202 31,44,523 3.79%
Foreign Nationals (FN) 1 13,69,840 1.65%
Clearing Members & Trusts 4 10,635 0.01%
Total Public Shareholding 48,941 6,55,49,280 79.06%
Total Capital Base 48,957 8,29,13,915 100.00%

The two single largest institutional and corporate blocks of shares outside the direct promoter family are held by BBR Projects Private Limited (11.45%) and Kitara PIIN 1102 (9.37%). Promoters and Persons Acting in Concert (PAC) together control 20.94% of the paid-up capital.

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

The operational and geographical scope of Vivimed Labs spans domestic R&D subsidiaries alongside international holding and marketing vehicles. Form AOC-1 summarizes the financial position and performance of the group’s subsidiary and associate entities for FY 2024-25:

Entity Name Relationship Country % Shareholding Reporting Turnover (₹ Crores) Profit / (Loss) After Tax (₹ Crores) Total Assets (₹ Crores) Total Liabilities (₹ Crores)
Finoso Pharma Private Limited Direct Subsidiary India 100.00% 17.50 (0.09) 26.04 26.04
Vivimed Holdings Limited Direct Subsidiary Hong Kong 100.00% 0.00 (0.04) 302.48 302.48
Vivimed Labs USA Inc. Direct Subsidiary USA 100.00% 0.00 (0.32) 106.84 106.84
Vivimed Labs Mauritius Limited Direct Subsidiary Mauritius 100.00% 0.00 (0.03) 382.72 382.72
Yantra Green Power Private Limited Associate Company India – 0.00 (0.00) 3.16 3.16

Finoso Pharma represents the core domestic operating subsidiary, generating ₹1.75 Crores in operational turnover from formulation research services while recording a nominal net loss of ₹0.09 Crores. The statutory auditor issued a qualification regarding unassessed impairment on the parent’s carrying value of investments in subsidiaries and associates of ₹58.78 Crores.

Strategic Investments, Credit Facilities & Contingent Liabilities

Off-balance-sheet commitments, corporate guarantees, and ongoing tax litigations represent substantial contingent liabilities for the group:

  • Income Tax Claims Under Dispute: Outstanding income tax demands under appeal totaled ₹182.16 Crores as on March 31, 2025, an increase from ₹111.06 Crores as of March 31, 2024.
  • Bank Guarantees: Outstanding bank guarantee commitments stood at ₹0.52 Crores (reduced from ₹4.51 Crores in FY 2023-24).
  • Corporate Guarantees: The company maintains outstanding corporate guarantees of ₹0.23 Crores issued on behalf of subsidiary undertakings.
  • Related Party Balances: Total non-current payables to related entities stood at ₹410.76 Crores, including payables to BBR Green Fields Private Limited of ₹50.57 Crores and Vivimed Labs Mauritius Limited of ₹96.79 Crores.

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

Despite severe balance-sheet stress, Vivimed Labs retains tangible pharmaceutical assets and capabilities:

  • Regulatory Accreditations: Facilities equipped to meet Health Canada and PIC/S GMP standards provide entry access to semi-regulated and regulated markets that command higher gross margins than commoditized domestic merchant formulations.
  • Formulation Pipeline: Proprietary formulation development through Finoso Pharma has generated ready-to-license dossiers in cardiovascular and anti-histamine categories (such as Bilastine, Rivaroxaban, and Edoxaban).
  • Established Export Registrations: Active product approvals and commercial relationships across Canada, Ukraine, Uzbekistan, Kyrgyzstan, and Azerbaijan provide a foundation for incremental export revenue recovery without requiring large-scale new capital outlays.

What Could Go Wrong? Key Challenges & Business Risks

Vivimed Labs operates under severe strategic, legal, and operational risks that challenge its ongoing recovery:

  • NPA Debt Defaults & Insolvency Exposure: With ₹374.46 Crores in recorded defaults and DRT proceedings initiated by the State Bank of India, failure to conclude a mutually agreed One-Time Settlement (OTS) or comprehensive loan restructuring poses a material insolvency risk.
  • Capital Inadequacy and Negative Net Worth: Consolidated net worth stands at -₹35.17 Crores, while annual unaccrued interest liabilities of ₹57.44 Crores continue to compound the group’s underlying obligations.
  • Trading Suspension on Exchanges: Equity shares remain suspended from active trading on both the BSE and NSE for penal reasons, restricting market liquidity for shareholders and complicating equity-linked capital raising.
  • Domestic Field Force Disruption: High attrition rates and compensation mismatches across medical representatives in the domestic branded division have led to lower revenue generation in India.
  • Statutory & Audit Trail Non-Compliances: The statutory auditors issued qualified audit opinions covering five critical areas: unaccrued interest, missing direct bank balance confirmations, unconfirmed debtor/creditor balances, non-identification of MSME suppliers, and absence of impairment testing on investments. Accounting software audit-trail (edit log) features were also not enabled throughout the year at the database level for the parent entity.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

The forward operational roadmap of Vivimed Labs centers on monetization of its existing regulatory pipeline and recapitalization of its balance sheet:

  • Canadian Portfolio Commercialization: Following the successful market launch of Chlorthalidone and approvals for Allopurinol (100mg, 200mg, 300mg), the company is preparing for the May 2026 commercial rollout of Empagliflozin (10mg and 25mg) in Canada, alongside ongoing CDMO negotiations for generic offtake.
  • CIS & Middle East Market Penetration: Commercial scaling of Bilastine in Kyrgyzstan (following initial orders) and anticipated Q1 FY 2025-26 approvals for Rupatidine and Bilastine. Active out-licensing of two product dossiers in Saudi Arabia is expected to open recurring licensing revenue streams across the GCC region.
  • Enabling Resolution for ₹500 Crore Capital Raise: At the 37th Annual General Meeting, the Board submitted a special resolution seeking shareholder approval to issue securities (including equity shares, QIP, FCCBs, ADRs, or non-convertible debt) for an aggregate amount of up to ₹500 Crores to repay existing debts, settle vendor obligations, and fund ongoing working capital requirements.

The Verdict: Strategic Outlook & Conclusion

Vivimed Labs Limited stands at a critical juncture in its corporate lifecycle. The successful pruning of non-core specialty chemical assets and the focus on formulations and research-driven CDMO exports have helped reduce annual operating losses and generated momentum across emerging market registrations. However, the company’s financial stability remains dependent upon its ability to achieve an agreed debt settlement with its lending syndicate, address its negative net worth, and secure new equity capital under its proposed ₹500 Crore issuance program.

Frequently Asked Questions (FAQs) About Vivimed Labs

Q1: What are the primary business divisions and products of Vivimed Labs?

Vivimed Labs operates primarily in the Pharmaceuticals sector, focusing on Finished Dosage Formulations (FDF) and CDMO services. Key commercialized products include Bilastine (anti-allergy), Rivaroxaban and Edoxaban (anticoagulants), Chlorthalidone and Allopurinol (cardiovascular and gout therapies), and various ophthalmic formulations.

Q2: What were the revenue and net profit figures of Vivimed Labs for FY 2024-25?

On a consolidated Ind AS basis for FY 2024-25, Vivimed Labs reported Revenue from Operations of ₹116.27 Crores (Total Income of ₹120.64 Crores) and a Net Loss After Tax of ₹31.96 Crores, compared to revenue of ₹149.07 Crores and a net loss of ₹45.45 Crores in FY 2023-24.

Q3: Who manages Vivimed Labs and what is the shareholding pattern?

The company is managed by Mr. Santosh Varalwar (Managing Director) and Dr. Manohar Rao Varalwar (Chairman cum Whole Time Director). As of March 31, 2025, the Promoter and Promoter Group holds 20.94% of equity capital, with BBR Projects Private Limited holding 11.45%. Public and non-institutional shareholders own 79.06%, including foreign institutional shareholder Kitara PIIN 1102 with 9.37%.

Q4: Where are Vivimed Labs’ manufacturing facilities and R&D centres located?

The company has six manufacturing sites located in Bidar (Karnataka), Jeedimetla (two units in Hyderabad, Telangana), Kashipur (two units in Uttarakhand), Haridwar (Uttarakhand), and Goregaon (Mumbai, Maharashtra). Its central formulation R&D center is situated in Nacharam, Hyderabad.

Q5: What is the current debt status and financial situation of Vivimed Labs?

The company has defaulted on bank borrowings totaling ₹374.46 Crores, which are classified as Non-Performing Assets (NPAs). Lead lender State Bank of India has initiated proceedings before the Debts Recovery Tribunal (DRT). Consolidated net worth stands at -₹35.17 Crores. The company is actively negotiating One-Time Settlements (OTS) with lenders and seeking approval to raise up to ₹500 Crores in fresh securities.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.vivimedlabs.com